Alexandre Bazinet

Alexandre Bazinet is an Assistant Professor at The University of Texas MD Anderson Cancer Center, specializing in hematology and oncology. His research focuses on acute myeloid leukemia, myelodysplastic neoplasms, and chronic myelomonocytic leukemia, with particular emphasis on genomic determinants, measurable residual disease, and novel pharmacotherapies such as menin inhibitors and venetoclax-based regimens. His recent publications include studies on immunophenotypic changes following menin inhibition in AML, molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms, and the clinical features of POT1 tumor predisposition syndrome. He has also investigated the impact of frontline intensive chemotherapy consolidation cycles and myeloablative conditioning regimens for high-risk MDS. His work integrates clinical, genetic, and familial data to advance diagnostic accuracy and therapeutic outcomes in hematological malignancies.